BRNS

Barinthus Biotherapeutics plc

• TipRanks·4d ago

  Barinthus Biotherapeutics appoints Douglas Swirsky as CFO

• TipRanks·03/31 23:50

  Barinthus Biotherapeutics Announces Upcoming Accounting Leadership Change

• TipRanks·03/16 10:20

  Wall Street Analysts Are Bullish on Top Healthcare Picks

• Seeking Alpha·03/13 19:14

  Barinthus Biotherapeutics GAAP EPS of -$1.64

• TipRanks·03/13 12:28

  Barinthus Bio Announces 2025 Results and Clywedog Merger

• TipRanks·03/13 12:08

  Barinthus Biotherapeutics reports FY25 EPS ($1.64) vs ($1.55) last year

• TipRanks·02/23 11:32

  Barinthus Biotherapeutics Amends Cross-Border Merger Agreement Terms

• TipRanks·01/06 21:31

  Barinthus Biotherapeutics Receives Nasdaq Minimum Bid Price Notice

• NASDAQ·12/15/2025 17:00

  Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Buy: What Does It Mean for the Stock?

• TipRanks·12/11/2025 11:16

  Promising Clinical Trial Results and Strategic Merger Drive Buy Rating for Barinthus Biotherapeutics

• TipRanks·12/10/2025 13:28

  Barinthus Biotherapeutics Updates on AVALON Trial Progress

• TipRanks·12/10/2025 13:16

  Barinthus Biotherapeutics announces update on Phase 1 trial of VTP-1000

• Dow Jones·11/17/2025 12:39

  Barinthus Biotherapeutics Price Target Raised to $4.00/Share From $3.00 by HC Wainwright & Co.

• Dow Jones·11/17/2025 12:39

  Barinthus Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.

• TipRanks·11/17/2025 11:35

  Buy Rating for Barinthus Biotherapeutics: Promising Clinical Developments and Strategic Merger with Clywedog Therapeutics